RxDoctor Payments Data

Benjamin Peng, MD

Urology · New York, NYNPI 1356303739

Payments from drug & device makers

$4,866in general payments, 2019–2025

Across 166 payments — averaging $29.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Astellas Pharma US Inc$877
  • Boston Scientific$422
  • Neotract Inc.$374
  • Verity Pharmaceuticals Inc.$242
  • Pfizer$214
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,17086%
  • Education$69614%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,866 in reported general payments places this provider in the 60th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$182,001
Medicare patients
201
Services billed
1,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron518$543,489
OrgovyxRelugolix12$31,982
Silodosin238$29,360
Desmopressin AcetateDesmopressin (Nonrefrigerated)174$9,713
Potassium Citrate ErPotassium Citrate148$9,470
Finasteride881$8,430
Tamsulosin Hcl887$8,007
PremarinEstrogens, Conjugated11$4,931
Bethanechol Chloride132$3,805
Solifenacin Succinate37$3,644
Dutasteride89$3,360
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst161$3,204
Desmopressin Acetate16$2,826
ValacyclovirValacyclovir Hcl71$2,514
Alfuzosin Hcl ErAlfuzosin Hcl106$2,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$877$543,489518 claims
Sumitomo Pharma America, Inc.Orgovyx$154$31,98212 claims
PfizerPremarin$214$4,93111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 952 urology providers in New York.

Other urology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →